title: Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
abstract: OBJECTIVE
  It is largely unknown how the medical treatment of patients diagnosed with dementia is followed up in primary care. Therefore, we studied patient medical records from two dementia clinics and from the referring primary care centres.
  
  
  METHODS
  A retrospective study of 241 patients was conducted from April to October 2011 in north west Stockholm, Sweden. Over half (51.5%) of the patients had Alzheimer's disease (AD), the remainder had mixed AD/vascular dementia (VaD). Eighty-four medical reports from primary care (35% of the study group) were analysed at follow-up 18 months after diagnosis.
  
  
  RESULTS
  All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics. The most commonly used dementia drug was galantamine. There were differences between the two dementia clinics in preference and combination of drugs and of treatment given to male and female patients. At follow-up, 84% were still on dementia medication. Drug use was followed up by the general practitioners (GPs) in two-thirds of the cases. Eighteen per cent of the GPs' medical records made no reference to the patient's dementia or treatment even though dementia drugs were included in the list of medications prescribed.
  
  
  CONCLUSIONS
  The results indicate that the Swedish guidelines for treatment of cognitive symptoms in AD are being followed in primary care. However, documentation of follow-up of drug treatment was sometimes insufficient, which calls for development of guidelines for complete medical records and medication lists.
authors: FOU nu-Research and Development Centre, Stockholm, Sweden. lars.sonde@aldrecentrum.se
authors: Lars
authors: L
authors: Sonde
authors: Kristina
authors: K
authors: Johnell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D003704:Dementia / Q000188:drug therapy / Q000503:physiopathology; D015140:Dementia, Vascular / Q000188:drug therapy / Q000503:physiopathology; D000077265:Donepezil; D005260:Female; D005702:Galantamine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008499:Medical Records / Q000706:statistics & numerical data*; D008559:Memantine / Q000494:pharmacology / Q000627:therapeutic use; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000941:ethics*; D011320:Primary Health Care / Q000941:ethics / Q000458:organization & administration / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D000068836:Rivastigmine; D013548:Sweden; D016896:Treatment Outcome
chemical_list: D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine